Advertisement
ORKA vs XNCR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORKA is a StrongBuy and XNCR is a Hold.
ORKA in +0.94% Uptrend, advancing for three consecutive days on October 30, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ORKA advanced for three days, in 203 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on ORKA as a result. In 67 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for ORKA just turned positive on October 21, 2026. Looking at past instances where ORKA's MACD turned positive, the stock continued to rise in 39 of 54 cases over the following month. The odds of a continued upward trend are 72%.
ORKA moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ORKA crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORKA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
ORKA broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ORKA entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.929) is normal, around the industry mean (3.051). P/E Ratio (-48.799) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ORKA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORKA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
XNCR in upward trend: 10-day moving average crossed above 50-day moving average on October 28, 2026
The 10-day moving average for XNCR crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XNCR as a result. In 52 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for XNCR just turned positive on October 21, 2026. Looking at past instances where XNCR's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.
XNCR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +19.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where XNCR advanced for three days, in 188 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 51 cases where XNCR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XNCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
XNCR broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XNCR entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.527) is normal, around the industry mean (3.051). P/E Ratio (-14.185) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.740) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (16.949) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. XNCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XNCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ORKA | XNCR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 33 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 18 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 97 | |
PRICE GROWTH RATING 1..100 | 35 | 34 | |
P/E GROWTH RATING 1..100 | 58 | 94 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ORKA's Valuation (4) in the null industry is in the same range as XNCR (18) in the Biotechnology industry. This means that ORKA’s stock grew similarly to XNCR’s over the last 12 months.
ORKA's Profit vs Risk Rating (100) in the null industry is in the same range as XNCR (100) in the Biotechnology industry. This means that ORKA’s stock grew similarly to XNCR’s over the last 12 months.
ORKA's SMR Rating (94) in the null industry is in the same range as XNCR (97) in the Biotechnology industry. This means that ORKA’s stock grew similarly to XNCR’s over the last 12 months.
XNCR's Price Growth Rating (34) in the Biotechnology industry is in the same range as ORKA (35) in the null industry. This means that XNCR’s stock grew similarly to ORKA’s over the last 12 months.
ORKA's P/E Growth Rating (58) in the null industry is somewhat better than the same rating for XNCR (94) in the Biotechnology industry. This means that ORKA’s stock grew somewhat faster than XNCR’s over the last 12 months.
| ORKA | XNCR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | 2 days ago 76% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 68% | 2 days ago 69% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 77% |
| TrendWeek ODDS (%) | 2 days ago 73% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 76% | 2 days ago 73% |
| Advances ODDS (%) | 6 days ago 79% | 9 days ago 74% |
| Declines ODDS (%) | 20 days ago 74% | 22 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 80% | 2 days ago 80% |
| Aroon ODDS (%) | 2 days ago 73% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ORKA’s FA Score shows that 1 FA rating(s) are green while XNCR’s FA Score has 1 green FA rating(s).
- ORKA’s FA Score: 1 green, 4 red.
- XNCR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ORKA’s TA Score shows that 5 TA indicator(s) are bullish while XNCR’s TA Score has 5 bullish TA indicator(s).
- ORKA’s TA Score: 5 bullish, 5 bearish.
- XNCR’s TA Score: 5 bullish, 5 bearish.
Price Growth
ORKA (@Biotechnology) experienced а +3.90% price change this week, while XNCR (@Biotechnology) price change was +2.17% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.61%. For the same industry, the average monthly price growth was -11.21%, and the average quarterly price growth was -16.43%.
Reported Earning Dates
ORKA is expected to report earnings on Nov 11, 2026.
XNCR is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-3.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ORKA and
Correlation & Price change
A.I.dvisor indicates that over the last year, ORKA has been loosely correlated with SYRE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ORKA jumps, then SYRE could also see price increases.
| Ticker / NAME | Correlation To ORKA | 1D Price Change % | ||
|---|---|---|---|---|
| ORKA | 100% | +4.32% | ||
| SYRE - ORKA | 51% Loosely correlated | +3.94% | ||
| XNCR - ORKA | 48% Loosely correlated | +3.30% | ||
| DNTH - ORKA | 44% Loosely correlated | +0.55% | ||
| TRVI - ORKA | 42% Loosely correlated | +1.69% | ||
| IMVT - ORKA | 42% Loosely correlated | +2.22% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DLAG | 33.57 | 0.06 | +0.16% |
| FT Vest U.S. Equity Dual Directional Buffer ETF - August (DLAG) | |||
| MEGX | 20.44 | N/A | N/A |
| Corgi U.S. Mega-Cap Growth 2x Daily ETF (MEGX) | |||
| VBCC | 74.29 | -0.02 | -0.03% |
| Vanguard Target Maturity 2029 Corporate Bond ETF (VBCC) | |||
| FTXH | 43.87 | -0.02 | -0.04% |
| First Trust Nasdaq Pharmaceuticals ETF (FTXH) | |||
| OPPE | 58.38 | -0.43 | -0.73% |
| WisdomTree European Opportunities Fund (OPPE) | |||